Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
April 08, 2023 at 15:20 PM EDT
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up to $1.5 billion in milestone payments.
